This site is intended for health professionals only

Sunday 19 May 2019
Share |

Topic: Latest News

May 9, 2019
The recommendation comes as a result of a significant volume of evidence that the use of PICO improves patient outcomes and provide additional benefits to the healthcare system at no extra cost versus standard care
Smith & Nephew welcomes the launch of new medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE). 
In the guidance, NICE recommends that PICO Single Use Negative Pressure Wound Therapy System (sNPWT) should be considered as an option for closed surgical incisions in patients who are at high risk of surgical site infections (SSIs).1 Key patient risk factors include a high BMI, diabetes, renal insufficiency and smoking.2
May 9, 2019
Familial chylomicronaemia syndrome is a debilitating disease caused by impaired function of the enzyme lipoprotein lipase, which causes high circulating levels of triglycerides in the body, leading to extreme abdominal pain and episodes of potentially fatal pancreatitis
Akcea Therapeutics and Ionis Pharmaceuticals have announced that Waylivra (volanesorsen) has received conditional marketing authorisation from the European Commission as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.1
May 2, 2019
Crohn’s & Colitis UK announces targeted research call into pain, one of the most debilitating symptoms of these conditions
National charity Crohn’s & Colitis UK launches new research initiative that aims to understand what is unique about pain in people with inflammatory bowel disease (IBD), with the hope of preventing and managing this symptom and improving quality of life for people who suffer with it.
May 2, 2019
Clinical Fellow Ben Shelley is driving forward the chronic pain trial at the Golden Jubilee Hospital in Scotland
Researchers at the Golden Jubilee National Hospital in Scotland have recruited the first patients for a new trial which aims to reduce chronic pain following open lung surgery.
The first patients have been recruited and operated on within 24 hours of the TOPIC2 trial, which is funded by the National Institute for Health Research Health Technology Assessment Programme, starting at the National Hospital – the only Scottish centre participating in the UK multi centre trial.
May 2, 2019
A de-escalation strategy omitting chemotherapy in the first line treatment of HER2 positive metastatic breast cancer was attempted in the PERNETTA trial
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr Carmen Criscitiello, European Institute of Oncology, Milan, Italy. 
Her comments come on the occasion of the presentation of updated research results at the inaugural ESMO Breast Cancer Congress 2019, 2-4 May 2019, in Berlin, Germany. 
May 2, 2019
The prospect of a CT scan can be scary for a child, but one student from the University of Salford in the UK is aiming to change that with her new business, ‘Stick with It’
CT scans are often difficult for children as they require the patient to lie completely still for a lengthy period of time. The scan can also be frightening due to its claustrophobic nature and loud volume.
Practitioners frequently report problems with getting children to comply; even the comforting presence of a parent or carer is made problematic by the lead-lined gowns they are forced to wear if they wish to remain in the room.
May 2, 2019
Pancreatic Cancer UK has announced that they are investing £750,000 into developing the first simple test for pancreatic cancer by 2024
Currently, pancreatic cancer is diagnosed by a CT or MRI scan and there is currently no ‘non-invasive’ detection test so a development of one would be welcomed.
However, whilst having a bio-marker for the disease is fantastic and something we should be investing in, this will not solve the problem of late diagnosis (which is the major cause for the extremely low survival rate in pancreatic cancer).  
April 29, 2019
All opioid medicines in the UK will now carry addiction warnings on their labels, the health secretary has announced.

All opioid medicines in the UK will now carry addiction warnings on their labels, the health secretary has announced.

April 25, 2019
This major breakthrough and world-first could hail a new era in the design and production of new antibiotics and anticancer agents
After 20 years of dedicated research, scientists have cracked the chemical code of an incredibly complex 'anti-tumour antibiotic' known to be highly effective against cancer cells as well as drug-resistant bacteria, and have reproduced it synthetically in the lab for the first time.
April 23, 2019
Scientists from the Cancer Research UK Manchester Institute at The University of Manchester showed that a small volume of blood can contain up-to-date genetic information about a patient's cancer to inform treatment choices

Scientists could help match cancer patients with no other treatment options to clinical trials with experimental medicines, by analysing the genetic faults in a sample of their blood, according to research published in Nature Medicine.

The researchers, funded by Cancer Research UK, The Christie Charity, AstraZeneca and the NIHR Manchester Biomedical Research Centre (BRC), demonstrated in their feasibility study that a blood test can be carried out and analysed in a timeframe that can help clinicians select a matched, targeted treatment.

April 15, 2019
This collaboration is expected to take several forms, including joint design and implementation of clinical research, working meetings at scientific conferences, cross-entity working groups with diverse functional group participation and clinical trial innovations
The US-based Antibacterial Resistance Leadership Group (ARLG), part of the Duke Clinical Research Institute (DCRI) and the University Medical Center (UMC) Utrecht, the managing entity of the COMBACTE (Combatting Bacterial Resistance in Europe) consortium, will work together to solidify a comprehensive global community to combat the threat of antibiotic resistance around the world.
April 12, 2019
Research conducted at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University, UK aimed to understand the development of bacterial resistance to four different topical antibiotics commonly used in some OTC sore throat medicines
Research presented at the 2019 European Congress of Clinical Microbiology & Infectious Diseases shows that the inappropriate of use of antibiotics legitimately available in over-the-counter (OTC) throat medications could be contributing to antibiotic resistance, thereby going against World Health Organization (WHO) goals.
April 12, 2019
Improving results for patients by realising the transformational potential of Real World Data
HONEUR (Haematology Outcomes Network in Europe) is a Janssen-led initiative and part of the company’s overall commitment to creating better outcomes for patients – in this case, by harnessing the full potential of Real World Data and the insights it can provide. 
April 10, 2019
European health insurance cards (EHIC) may no longer be valid in the event of a no-deal Brexit, the Department of Health and Social Care has said.

European health insurance cards (EHIC) may no longer be valid in the event of a

April 10, 2019
In oncology, in particular, where there are often no alternatives to these medicines, shortages pose a threat to patient safety as they reduce adherence to therapy and limit the ability of physicians to provide effective treatment regimens

Shortages of essential cancer medicines have a direct impact on patient care across Europe.

To ensure that this issue remains a top priority on the EU policy agenda, ESMO collaborated with the European Parliament to organise a cross-partisan event entitled “Shortages of Inexpensive, Essential Medicines: Calling for Tangible Political Commitments in the EU”.1

April 10, 2019
Those who qualified in the European Union (EU) can continue to practise in the UK after Brexit, even in a no-deal scenario, the Government has confirmed.

Healthcare professionals who qualified in the European Union (EU) can continue to practise in the UK after Brexit, e

April 10, 2019
Modelling study shows that up to 43% of the world’s future hepatitis C infections could be prevented if transmission among people who inject drugs was reduced

Stepping up efforts to prevent transmission of hepatitis C among people who inject drugs, could reduce future infections by 43% globally, according to a study by researchers at the University of Bristol published in the Lancet Gastroenterology and Hepatology.1

April 10, 2019
First PARP inhibitor approved in the EU for patients with this difficult-to-treat disease and third EU approval for Lynparza

The European Commission has approved Lynparza (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.

April 9, 2019
NHS England has said it is going to ‘formally request’ that the Government bans GPs from prescribing homeopathy.

NHS England has said it is going to "formally request" that the Government bans GPs from prescribing homeo

April 8, 2019
The European Centre for Disease Prevention and Control estimates that a severe pandemic could infect up to a quarter of the population of the European Union, with many millions of cases and tens of thousands of deaths
Seqirus has signed contracts with the European Commission and 15 European Union Member States to supply pandemic influenza vaccines as part of the response to a pandemic emergency. 
It is the first influenza vaccine manufacturer to sign pandemic contracts under the EU joint procurement framework.
April 8, 2019
A clinical review published in the BMJ provides new interim advice for doctors and clinicians in prescribing cannabis-based products and cannabinoids to treat certain conditions
Since a policy change in November 2018, specialist doctors registered with the General Medical Council (GMC), have been permitted to prescribe new medicines which derive from cannabis. Yet, research into these products has, to date, been limited creating an 'information vacuum' about these medicines, their benefits or harms.
April 5, 2019
Immediate first-line access to this combination could be a treatment option for up to 1700 advanced kidney cancer patients in England
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) to treat NHS patients in England with renal cell carcinoma (RCC). 
April 5, 2019
The UK medicines watchdog has issued guidance on fluoroquinolone antibiotics following some reports of ‘potentially irreversible’ side effects affecting multiple systems, organ classes and senses

The UK medicines watchdog has issued guidance on fluoroquinolone antibiotics following some reports of ‘potentially irreversible’ side effects affecting multiple systems, organ classes and senses.

The Medicines and Healthcare Regulatory Authority (MHRA) cautioned healthcare professionals on 21 March against prescribing the drug and to advise patients to stop taking it if they experienced side effects including muscle pain and peripheral neuropathy.

March 28, 2019
New immunotherapy drug targets for cancer will be progressed through a multimillion-pound drug discovery alliance between Cancer Research UK, LifeArc and Ono Pharmaceutical Co Ltd
A multi-year partnership brings together Cancer Research UK’s network of world-leading scientists and drug discovery expertise, LifeArc’s renowned therapeutic antibody engineering and development expertise, and Ono’s considerable track record in developing cancer immunotherapies.